Login / Signup

Safety, efficacy and cost of two direct-acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients.

Abdel-Hameed Ibrahim Mohammed EbidOsama Ashraf AhmedSara Hassan AgwaSara Mohamed Abdel-MotalebAmira Mohamed ElsawyRadwa Samir Hagag
Published in: Journal of clinical pharmacy and therapeutics (2019)
The two DAA regimens showed high SVR12 and safety in Egyptian HCV G4 patients. Sofosbuvir plus daclatasvir is the cost-saving regimen.
Keyphrases
  • hepatitis c virus
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • peritoneal dialysis
  • prognostic factors
  • human immunodeficiency virus
  • patient reported outcomes
  • patient reported